Durvalumab and Chemotherapy Induction Followed by Durvalumab and Radiotherapy in Large Volume Stage III NSCLC

NCT04765709 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

10

Enrollment

OTHER

Sponsor class

Stopped Low enrolment rate

Conditions

Non-small Cell Lung Cancer Stage III

Interventions

COMBINATION_PRODUCT: durvalumab plus platinum-based chemotherapy (cisplatin or carboplatin plus vinorelbine or pemetrexed)
COMBINATION_PRODUCT: Durvalumab plus radiotherapy
BIOLOGICAL: durvalumab

Sponsor

Mario Negri Institute for Pharmacological Research

Collaborators

AstraZeneca
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano